Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Loxo Oncology Inc    LOXO

LOXO ONCOLOGY INC (LOXO)
My previous session
Most popular
  Report  
Delayed Quote. Delayed  - 01/22 04:00:00 pm
233.78 USD   +0.12%
01/08Lilly's Deal Boosts Its Cancer Arsenal -- WSJ
DJ
01/07Eli Lilly to Buy Loxo Oncology in $8 Billion Deal -- 5th Update
DJ
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/15/2019 01/16/2019 01/17/2019 01/18/2019 01/22/2019 Date
233.67(c) 233.26(c) 233.25(c) 233.5(c) 233.78(c) Last
1 590 575 2 673 827 2 479 692 1 541 340 1 039 129 Volume
+0.49% -0.18% 0.00% +0.11% +0.12% Change
More quotes
Financials (USD)
Sales 2018 178 M
EBIT 2018 -71,4 M
Net income 2018 -58,8 M
Finance 2018 795 M
Yield 2018 -
Sales 2019 198 M
EBIT 2019 -104 M
Net income 2019 -87,1 M
Finance 2019 694 M
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales2018 35,6x
EV / Sales2019 32,6x
Capitalization 7 148 M
More Financials
Company
Loxo Oncology, Inc. is a biopharmaceutical company. The Company is focused on development of medicines for patients with genetically defined cancers. The Company's pipeline focuses on cancers that are dependent on single gene abnormalities, such that a single drug has the potential to treat the... 
More about the company
Surperformance© ratings of Loxo Oncology Inc
Trading Rating : Investor Rating :
More Ratings
Latest news on LOXO ONCOLOGY INC
01/19LOXO ONCOLOGY : Eli Lilly`s buyout of Loxo Oncology took only 2 weeks
AQ
01/17LOXO ONCOLOGY : Eli Lilly`s modernisation plan cuts 250 jobs in France
AQ
01/09LOXO ONCOLOGY : Lilly to acquire Loxo Oncology in deal valued at $8bn
AQ
01/08GlaxoSmithKline to look for early-stage assets - CEO
RE
01/08ELI LILLY AND : Lilly Announces Agreement To Acquire Loxo Oncology
AQ
01/08SECOND BIG M&A DEAL OF 2019 : Lilly to acquire Loxo
AQ
01/08LOXO ONCOLOGY : Eli Lilly to buy Loxo Oncology for $8 billion in huge bet on can..
AQ
01/08Lilly's Deal Boosts Its Cancer Arsenal -- WSJ
DJ
01/08LOXO ONCOLOGY : Eli Lilly makes a $8bn move for Loxo Oncology
AQ
01/07Lilly makes $8 billion bet on drugs for rare cancers with Loxo Oncology buy
RE
More news
Analyst Recommendations on LOXO ONCOLOGY INC
More recommendations
Sector news : Bio Therapeutic Drugs
01/18Samsung Bioepis biosimilar to Roche's Herceptin wins FDA nod
RE
01/08NEKTAR THERAPEUTICS : Shares Up Tuesday as Gilead Collaboration Announced -- Mar..
DJ
01/07MERCK AND : loses bid to revive $200 million Gilead verdict at U.S. high court
RE
01/07Sanofi, Regeneron Restructure Immuno-Oncology Agreement
DJ
01/05SOUTH KOREA'S CELLTRION AIMS TO SET : chairman
RE
More sector news : Bio Therapeutic Drugs
Chart LOXO ONCOLOGY INC
Duration : Period :
Loxo Oncology Inc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends LOXO ONCOLOGY INC
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 12
Average target price 225 $
Spread / Average Target -3,6%
EPS Revisions
Managers
NameTitle
Joshua H. Bilenker President, Chief Executive Officer & Director
Jacob S. van Naarden Chief Operating Officer
Jennifer Burstein Senior Vice President-Finance
S. Michael Rothenberg Vice President-Research & Development
Deborah Morosini VP-Clinical Affairs & Patient Engagement
Sector and Competitors
1st jan.Capitalization (M$)
LOXO ONCOLOGY INC66.90%7 148
GILEAD SCIENCES9.59%89 493
VERTEX PHARMACEUTICALS17.00%49 757
REGENERON PHARMACEUTICALS8.37%44 532
GENMAB-3.09%9 527
NEUROCRINE BIOSCIENCES, INC.27.83%8 300